OBJECTIVE: This is the first study to investigate the Quality of Life (QOL) of patients with Gilles de la Tourette's Syndrome (GTS). METHOD: One hundred and three out-patients with GTS completed a semi-structured interview and 90 of these completed questionnaires screening for depression, anxiety and obsessive-compulsive behaviour. QOL was measured with the SF-36 and the Quality of Life Assessment Schedule (QOLAS). RESULTS: Patients with GTS showed significantly worse QOL than a general population sample. They had better QOL than patients with intractable epilepsy as measured by the QOLAS, although the SF-36 showed significant differences on the subscales Role Limitation due to physical problems and Social Functioning only. Factors influencing QOL domains were employment status, tic severity, obsessive-compulsive behaviour, anxiety and depression. CONCLUSION: QOL is impaired in patients with GTS. Measurement of QOL could be used alongside conventional measurements to assess benefit of treatment. We recommend the QOLAS and SF-36 be used.
OBJECTIVE: This is the first study to investigate the Quality of Life (QOL) of patients with Gilles de la Tourette's Syndrome (GTS). METHOD: One hundred and three out-patients with GTS completed a semi-structured interview and 90 of these completed questionnaires screening for depression, anxiety and obsessive-compulsive behaviour. QOL was measured with the SF-36 and the Quality of Life Assessment Schedule (QOLAS). RESULTS:Patients with GTS showed significantly worse QOL than a general population sample. They had better QOL than patients with intractable epilepsy as measured by the QOLAS, although the SF-36 showed significant differences on the subscales Role Limitation due to physical problems and Social Functioning only. Factors influencing QOL domains were employment status, tic severity, obsessive-compulsive behaviour, anxiety and depression. CONCLUSION: QOL is impaired in patients with GTS. Measurement of QOL could be used alongside conventional measurements to assess benefit of treatment. We recommend the QOLAS and SF-36 be used.
Authors: P Paschou; Y Feng; A J Pakstis; W C Speed; M M DeMille; J R Kidd; B Jaghori; R Kurlan; D L Pauls; P Sandor; C L Barr; K K Kidd Journal: Am J Hum Genet Date: 2004-08-09 Impact factor: 11.025
Authors: Daniel A Gorman; Nancy Thompson; Kerstin J Plessen; Mary M Robertson; James F Leckman; Bradley S Peterson Journal: Br J Psychiatry Date: 2010-07 Impact factor: 9.319
Authors: Christine A Conelea; Douglas W Woods; Samuel H Zinner; Cathy L Budman; Tanya K Murphy; Lawrence D Scahill; Scott N Compton; John T Walkup Journal: Community Ment Health J Date: 2011-11-04
Authors: Hilary Weingarden; Lawrence Scahill; Susanne Hoeppner; Alan L Peterson; Douglas W Woods; John T Walkup; John Piacentini; Sabine Wilhelm Journal: Compr Psychiatry Date: 2018-04-23 Impact factor: 3.735